Monitoring Report: GLP-1 RA Prescribing Trends – March 2026 Data

Samuel Gratzl, PhD

Karen Gilbert Farrar, PhD

Emma Holler, PhD

Madhura S Vachon, PhD

Nina Masters, MPH, PhD

Brianna M Goodwin Cartwright, MS

Affiliations: All authors are affiliated with Truveta, Inc.

Corresponding author:
Brianna Cartwright
Truveta, Inc
1745 114th Ave SE, Bellevue, WA 98004
Email: briannac@truveta.com

Abstract

Background: Limited recent data exist on prescribing patterns and patient characteristics for glucagon-like peptide 1 receptor agonists (GLP-1 RAs), an important drug class used as anti-diabetic medication (ADM) for patients with type 2 diabetes mellitus (T2D) and/or anti-obesity medication (AOM) in patients with overweight or obesity.

For brevity, we use the term GLP-1 RA to refer to both GLP-1 RA and dual GLP-1 RA/GIP medications.

Objective: To describe recent trends in prescribing and dispensing of GLP-1-based medications in the US.

Methods: Using a subset of real-world electronic health record (EHR) data from Truveta, a growing collective of health systems that provide more than 18% of all daily clinical care in the US, we identified people who were prescribed a GLP-1-based medication between January 01, 2019 and March 31, 2026. We describe prescribing volumes and patient characteristics over time, by medication, and by FDA-labeled use. Among the subset of patients for whom post-prescription dispensing data is available, we describe the proportion and characteristics of patients who were and were not dispensed a GLP-1 RA following their prescription.

Results: 2,855,602 patients were prescribed a GLP-1 RA between January 2019 and March 2026, with 14,738,765 total prescriptions during this period. Overall prescribing rates (GLP-1 RA prescriptions as a proportion of all prescriptions) increased by more than one percentage point from December 2025 to March 2026 (+15.0%), representing the largest quarter-over-quarter percentage point increase observed since the start of the study period in 2019. AOM semaglutide similarly demonstrated its largest quarter-over-quarter percentage point increase during this most recent quarter. Among first-time prescriptions for which use could be established, ADMs accounted for 67.6% and AOMs accounted for 32.4%. First-time AOM prescribing rose by 21.7% from December 2025 to March 2026, with first-time prescribing of AOM semaglutide increasing by more than 50%. This marks the largest quarter-over-quarter increase in first-time AOM semaglutide prescribing since mid-2024. These trends in both overall and first-time AOM semaglutide prescribing are likely driven by the approval of the oral formulation of AOM semaglutide in December 2025.

Trends in Prescribing







	GLP-1 RA	Semaglutide	Tirzepatide	Liraglutide	Dulaglutide	Other
Overall						
December 2025	6.73%	2.59%	3.85%	0.08%	0.34%	0.01%
March 2026	7.74%	3.10%	4.38%	0.08%	0.35%	0.01%
Change (percentage)	+15.01%	+19.62%	+13.92%	+2.88%	+2.80%	+3.68%
Difference (percentage points)	+1.01%	+0.51%	+0.54%	+0.00%	+0.01%	+0.00%
ADM						
December 2025	3.26%	1.17%	1.76%	0.00%	0.34%	0.01%
March 2026	3.42%	1.14%	1.95%	0.00%	0.35%	0.01%
Change (percentage)	+4.73%	-2.43%	+10.33%	-1.42%	+2.80%	+3.68%
Difference (percentage points)	+0.15%	-0.03%	+0.18%	-0.00%	+0.01%	+0.00%
AOM						

	GLP-1 RA	Semaglutide	Tirzepatide	Liraglutide	Dulaglutide	Other
December 2025	2.36%	0.79%	1.59%	0.02%	n/a	n/a
March 2026	2.91%	1.10%	1.85%	0.02%	n/a	n/a
Change (percentage)	+23.76%	+39.73%	+16.45%	-4.98%		
Difference (percentage points)	+0.56%	+0.31%	+0.26%	-0.00%		
Unknown						
December 2025	1.48%	0.71%	0.73%	0.06%	n/a	n/a
March 2026	1.83%	0.96%	0.84%	0.06%	n/a	n/a
Change (percentage)	+24.20%	+35.21%	+15.13%	+5.63%		
Difference (percentage points)	+0.36%	+0.25%	+0.11%	+0.00%		

- Overall prescribing rates (GLP-1 RA prescriptions per total prescriptions) in March 2026 increased by over one percentage point relative to December 2025 (+15.0%). This is the largest quarter-over-quarter percentage point increase reported since 2019 (beginning of the study period).
- Month-over-month ADM prescribing increased in January, remained stable in February, and increased again in March 2026. ADM prescribing in March 2026 increased slightly compared to December 2025 (+4.7%).
- Month-over-month AOM prescribing increased in each month between December 2025 and March 2026. Overall, there was a 0.6 percentage point increase compared to December 2025 (+23.8%). The largest increase came from AOM semaglutide prescriptions (+39.7%). This is the largest quarter-over-quarter percentage point increase in AOM semaglutide prescribing since 2019, likely due to the approval of the Wegovy pill in late 2025.
- Tirzepatide remains the most commonly prescribed GLP-1 RA, however semaglutide prescriptions, particularly AOM semaglutide prescriptions had the greatest percent increase over the last quarter.

Trends in First-Time Prescribing







	GLP-1 RA	Semaglutide	Tirzepatide	Liraglutide	Dulaglutide	Other
Overall						
December 2025	1.44%	0.57%	0.81%	0.01%	0.05%	0.00%
March 2026	1.64%	0.71%	0.87%	0.01%	0.04%	0.00%
Change (percentage)	+13.32%	+24.37%	+7.36%	-13.48%	-8.88%	-14.30%
Difference (percentage points)	+0.19%	+0.14%	+0.06%	-0.00%	-0.00%	-0.00%
ADM						
December 2025	0.53%	0.20%	0.27%	0.00%	0.05%	0.00%
March 2026	0.47%	0.16%	0.27%	0.00%	0.04%	0.00%
Change (percentage)	-9.83%	-19.87%	-2.41%	-39.30%	-8.88%	-14.30%
Difference (percentage points)	-0.05%	-0.04%	-0.01%	-0.00%	-0.00%	-0.00%
AOM						
December 2025	0.56%	0.18%	0.38%	0.00%	n/a	n/a
March 2026	0.69%	0.27%	0.42%	0.00%	n/a	n/a

	GLP-1 RA	Semaglutide	Tirzepatide	Liraglutide	Dulaglutide	Other
Change (percentage)	+21.71%	+51.74%	+8.18%	-12.77%		
Difference (percentage points)	+0.12%	+0.09%	+0.03%	-0.00%		
Unknown						
December 2025	0.37%	0.19%	0.17%	0.01%	n/a	n/a
March 2026	0.50%	0.28%	0.21%	0.01%	n/a	n/a
Change (percentage)	+32.85%	+45.99%	+20.91%	-11.97%		
Difference (percentage points)	+0.12%	+0.09%	+0.04%	-0.00%		

- First-time prescribing rates (first-time GLP-1 RA prescriptions per total prescriptions) in March 2026 increased compared with rates in December 2025 (+13.3%). First-time prescribing primarily increased between December 2025 and January 2026 and then remained stable at an elevated rate.
- First-time prescribing of ADMs decreased slightly in March 2026, relative to December 2025 (-9.8%).
- First-time prescribing of AOMs increased in March 2026, relative to December 2025 (+21.71%), with first-time prescribing of AOM semaglutide increasing by over 50%. This is the largest increase in first-time AOM semaglutide prescribing since mid-2024.

Trends in Dispensing



	GLP-1 RA	Semaglutide	Tirzepatide	Liraglutide	Dulaglutide	Other
Overall						

	GLP-1 RA	Semaglutide	Tirzepatide	Liraglutide	Dulaglutide	Other
September 2025	52.05%	53.52%	48.98%	60.28%	78.46%	67.06%
December 2025	50.59%	51.93%	48.07%	54.98%	75.77%	67.57%
Change (percentage)	-2.80%	-2.97%	-1.87%	-8.80%	-3.43%	+0.76%
Difference (percentage points)	-1.46%	-1.59%	-0.91%	-5.30%	-2.69%	+0.51%
ADM						
September 2025	71.47%	70.64%	70.75%	82.35%	78.46%	67.06%
December 2025	67.96%	67.00%	67.34%	60.61%	75.77%	67.57%
Change (percentage)	-4.91%	-5.15%	-4.81%	-26.41%	-3.43%	+0.76%
Difference (percentage points)	-3.51%	-3.63%	-3.40%	-21.75%	-2.69%	+0.51%
AOM						
September 2025	44.41%	51.03%	41.29%	59.72%	n/a	n/a
December 2025	42.78%	47.76%	40.45%	51.14%	n/a	n/a
Change (percentage)	-3.68%	-6.42%	-2.03%	-14.38%		
Difference (percentage points)	-1.64%	-3.27%	-0.84%	-8.59%		
Unknown						
September 2025	35.44%	37.60%	31.31%	58.78%	n/a	n/a
December 2025	36.01%	39.38%	31.11%	54.35%	n/a	n/a
Change (percentage)	+1.62%	+4.73%	-0.65%	-7.54%		
Difference (percentage points)	+0.57%	+1.78%	-0.20%	-4.43%		

- During the full time period, 70.4% of GLP-1 RA prescriptions had a dispense within 60 days of their prescription (e.g., were initiated within 60 days).
- For patients first prescribed an ADM in December 2025, 68.0% filled a GLP-1 RA within 60 days. Initiation rates for ADM GLP-1 RA are about the same in December 2025, relative to September 2025 (-4.9%).
- For patients first prescribed an AOM in December 2025, 42.8% filled a GLP-1 RA within 60 days. Initiation rates for AOM GLP-1 RA are about the same in December 2025, relative to September 2025 (-3.7%).

About this report

This report provides recent trends in the prescribing and dispensing of glucagon-like peptide-1 receptor agonist (GLP-1 RAs)-based medications, including dual GLP-1 RA/gastric inhibitory polypeptide (GIP) over time, by medication, and by FDA-labeled use. We used near real-time, aggregated electronic health record (EHR) data from a collective of US healthcare systems to describe prescribing and dispensing of GLP-1 RA medications from January 2019 to March 2026.

Introduction

Obesity and type 2 diabetes mellitus (T2D) are interconnected epidemics with a high prevalence and individual and combined negative impacts on health (CDC, 2020, Hales, 2020). Glucagon-like peptide-1 receptor agonist (GLP-1 RAs) -based medications, including dual GLP-1 RA/gastric inhibitory polypeptide (GIP), have been shown to improve glycemic control in patients with T2D and reduce weight in patients with and without T2D (Davies, 2015, Davies, 2021, Garvey, 2023, Jastreboff, 2022, Wilding, 2023, Yeh, 2023). GLP-1 RA have also demonstrated cardiovascular benefit in patients with and without T2D (Lincoff, 2023, Ussher, 2023).

Interest in these medications has recently accelerated, largely for their weight-loss effects; however, limited empiric data exist on prescribing, dispensing, and patient characteristics. Access to and use of GLP-1 RA may be impacted by high cost, limited insurance coverage for patients without T2D and medication shortages.

Methods

Data

We evaluated prescribing and dispensing of GLP-1 RAs between January 2019 and March 2026 using a subset of Truveta Data. Truveta provides access to continuously updated, linked, and de-identified electronic health record (EHR) from a collective of US health care systems that provide 18% of all daily clinical care in the US, including structured information on demographics, encounters, diagnoses, vital signs (e.g., weight, BMI, blood pressure), medication requests (prescriptions), medication administration, laboratory and diagnostic tests and results (e.g., HbA1c tests and values), and procedures. Updated EHR data are provided daily to Truveta by member health care systems. In addition to EHR data for care delivered within Truveta member health care systems, medication dispensing and social drivers of health (SDOH) information are made available through linked third-party data. Medication dispense (via e-prescribing data) includes fills for prescriptions written both within and outside Truveta member health care systems, providing greater observability into patients' medication history. Medication dispense histories are updated at the time of the encounter and include fill dates, NDC or RxNorm codes, quantity dispensed, and days of medication supplied.

Population

We identified GLP-1 RA prescriptions (medication requests) and dispenses among adults using RxNorm and NDC codes for dulaglutide, exenatide, liraglutide, lixisenatide, semaglutide, and tirzepatide. Exenatide and lixisenatide were grouped as 'other' given small relative sizes. Brands were identified when possible using RxNorm and NDC codes. Brands labeled for treatment of T2D were classified as ADMs and brands labeled for treatment of overweight and obesity were classified as AOMs. When brand could not be established, the labeled use was classified as unknown.

Prescribing Analysis

Characteristics of patients ever prescribed a GLP-1 RA were summarized, including demographics, social drivers of health (SDOH), and presence of T2D and/or overweight or obesity. Characteristics are provided by medication and by year of first prescription.

Overall and first-time prescribing rates of GLP-1 RA were summarized over time by medication and labeled use. The prescribing rate was calculated monthly as the number of patients with a GLP-1 RA prescription divided by the number of patients with any prescription in the month. Absolute differences and percentage changes in the rate of GLP-1 RA prescribing over the most recent 3-month period were summarized overall and by medication and labeled use.

Dispensing Analysis

We describe the proportion of GLP-1 RA prescriptions (overall and first-time) with a dispense occurring within 60 days. Dispensing analyses were restricted to prescriptions for which complete 60-day dispensing outcomes could be observed. Dispensing outcomes were considered observable if (1) a dispense was recorded in the 60 days following the prescription, and/or (2) an encounter took place after the 60-day period ended (at which time any dispenses would be observed). To allow sufficient follow-up, we report dispensing with a 90-day delay. Given shortages and expected substitutions at the pharmacy, we considered the dispense of any GLP-1 RA , which could differ from the prescribed GLP-1 RA.

We plot the proportion of prescriptions (overall and first-time) dispensed within 60 days over time, by medication and use. Differences in dispensing were expected between ADMs and AOMs given ADMs are typically covered by insurance, whereas insurance coverage for AOMs is limited. As such, we provide dispensing rates stratified by FDA labeled use. Further, we stratify dispensing by age 65+ vs. 18-64 as a proxy for Medicare coverage. Medicare never provides coverage for AOMs, whereas commercial insurers may.

Results

Overall population

The demographics of patients by first-prescribed medication are as follows:

Table 1: Patient Characteristics by First-Prescribed GLP-1 RA Medication.

	Semaglutide	Tirzepatide	Liraglutide	Dulaglutide	Other	Overall
N	1,481,922 (100.00%)	792,287 (100.00%)	133,198 (100.00%)	328,613 (100.00%)	33,201 (100.00%)	2,769,221 (100.00%)
Age Group						
18-44	391,492 (26.42%)	247,701 (31.26%)	38,291 (28.75%)	46,611 (14.18%)	3,570 (10.75%)	727,665 (26.28%)
45-64	703,298 (47.46%)	380,768 (48.06%)	64,962 (48.77%)	162,167 (49.35%)	14,906 (44.90%)	1,326,101 (47.89%)
65+	387,132 (26.12%)	163,818 (20.68%)	29,945 (22.48%)	119,835 (36.47%)	14,725 (44.35%)	715,455 (25.84%)
Sex						
Female	963,916 (65.04%)	528,319 (66.68%)	91,962 (69.04%)	177,851 (54.12%)	17,304 (52.12%)	1,779,352 (64.25%)
Male	518,006 (34.96%)	263,968 (33.32%)	41,236 (30.96%)	150,762 (45.88%)	15,897 (47.88%)	989,869 (35.75%)
Race						
White	1,061,586 (71.64%)	583,122 (73.60%)	95,196 (71.47%)	219,963 (66.94%)	23,945 (72.12%)	1,983,812 (71.64%)
Black or African American	201,567 (13.60%)	91,475 (11.55%)	19,077 (14.32%)	54,268 (16.51%)	4,111 (12.38%)	370,498 (13.38%)
Asian	39,201 (2.65%)	18,144 (2.29%)	2,507 (1.88%)	9,494 (2.89%)	822 (2.48%)	70,168 (2.53%)
Unknown	100,840 (6.80%)	60,114 (7.59%)	8,687 (6.52%)	24,757 (7.53%)	2,449 (7.38%)	196,847 (7.11%)
Native Hawaiian or Other Pacific Islander	5,365 (0.36%)	2,417 (0.31%)	578 (0.43%)	1,454 (0.44%)	142 (0.43%)	9,956 (0.36%)
American Indian or Alaska Native	10,475 (0.71%)	4,297 (0.54%)	1,500 (1.13%)	2,505 (0.76%)	293 (0.88%)	19,070 (0.69%)
Other Race	62,888 (4.24%)	32,718 (4.13%)	5,653 (4.24%)	16,172 (4.92%)	1,439 (4.33%)	118,870 (4.29%)
Ethnicity						
Hispanic or Latino	175,503 (11.84%)	91,501 (11.55%)	15,504 (11.64%)	44,237 (13.46%)	4,127 (12.43%)	330,872 (11.95%)

	Semaglutide	Tirzepatide	Liraglutide	Dulaglutide	Other	Overall
Not Hispanic or Latino	1,220,318 (82.35%)	651,475 (82.23%)	109,804 (82.44%)	261,980 (79.72%)	26,702 (80.43%)	2,270,279 (81.98%)
Unknown	86,101 (5.81%)	49,311 (6.22%)	7,890 (5.92%)	22,396 (6.82%)	2,372 (7.14%)	168,070 (6.07%)
Characteristics						
Type II Diabetes	601,587 (40.60%)	226,217 (28.55%)	56,608 (42.50%)	228,985 (69.68%)	23,474 (70.70%)	1,136,871 (41.05%)
Overweight or Obesity	1,023,442 (69.06%)	573,292 (72.36%)	81,439 (61.14%)	167,999 (51.12%)	15,418 (46.44%)	1,861,590 (67.22%)
Labeled Use						
ADM	638,291 (43.07%)	322,732 (40.73%)	47,911 (35.97%)	328,613 (100.00%)	33,201 (100.00%)	1,370,748 (49.50%)
AOM	319,804 (21.58%)	306,708 (38.71%)	31,053 (23.31%)	n/a	n/a	657,565 (23.75%)
Unknown	523,827 (35.35%)	162,847 (20.55%)	54,234 (40.72%)	n/a	n/a	740,908 (26.76%)
Year						
2019	17,750 (1.20%)	n/a	24,319 (18.26%)	29,117 (8.86%)	7,703 (23.20%)	78,889 (2.85%)
2020	31,181 (2.10%)	n/a	18,490 (13.88%)	31,739 (9.66%)	5,772 (17.39%)	87,182 (3.15%)
2021	71,561 (4.83%)	n/a	22,395 (16.81%)	48,025 (14.61%)	4,899 (14.76%)	146,880 (5.30%)
2022	168,454 (11.37%)	26,129 (3.30%)	26,081 (19.58%)	70,297 (21.39%)	5,050 (15.21%)	296,011 (10.69%)
2023	377,133 (25.45%)	73,838 (9.32%)	23,625 (17.74%)	72,629 (22.10%)	4,537 (13.67%)	551,762 (19.92%)
2024	395,872 (26.71%)	202,078 (25.51%)	10,062 (7.55%)	41,699 (12.69%)	3,238 (9.75%)	652,949 (23.58%)
2025	332,274 (22.42%)	379,404 (47.89%)	6,664 (5.00%)	29,631 (9.02%)	1,749 (5.27%)	749,722 (27.07%)
2026	87,697 (5.92%)	110,838 (13.99%)	1,562 (1.17%)	5,476 (1.67%)	253 (0.76%)	205,826 (7.43%)
Comorbidity						
Asthma	210,223 (14.19%)	116,657 (14.72%)	20,027 (15.04%)	38,003 (11.56%)	3,268 (9.84%)	388,178 (14.02%)
CKD	185,532 (12.52%)	71,666 (9.05%)	16,910 (12.70%)	61,316 (18.66%)	6,199 (18.67%)	341,623 (12.34%)

	Semaglutide	Tirzepatide	Liraglutide	Dulaglutide	Other	Overall
COPD	73,778 (4.98%)	31,608 (3.99%)	7,396 (5.55%)	23,229 (7.07%)	2,366 (7.13%)	138,377 (5.00%)
Hyperlipidemia	760,021 (51.29%)	378,672 (47.79%)	56,234 (42.22%)	174,859 (53.21%)	17,315 (52.15%)	1,387,101 (50.09%)
Hypertension	772,251 (52.11%)	371,715 (46.92%)	64,944 (48.76%)	190,747 (58.05%)	19,304 (58.14%)	1,418,961 (51.24%)
Major Depression	176,773 (11.93%)	90,615 (11.44%)	17,303 (12.99%)	29,886 (9.09%)	2,654 (7.99%)	317,231 (11.46%)

Prescribing over time

Overall

We describe the monthly rate of prescriptions by medication and FDA labeled use over time:



First-time

We describe the monthly rate of first-time prescriptions by medication and FDA labeled use over time.



Characteristics of patients by year of first GLP-1 RA use are as follows:

Table 2: Patient Characteristics by Year of First GLP-1 RA Prescription.

	2019	2020	2021	2022	2023	2024	2025
N	78,889 (100.00%)	87,182 (100.00%)	146,880 (100.00%)	296,011 (100.00%)	551,762 (100.00%)	652,949 (100.00%)	749,722 (100.00%)

	2019	2020	2021	2022	2023	2024	2025
Age Group							
18-44	12,874 (16.32%)	14,911 (17.10%)	28,567 (19.45%)	71,089 (24.02%)	145,904 (26.44%)	180,726 (27.68%)	214,332 (28.59%)
45-64	42,116 (53.39%)	45,703 (52.42%)	74,871 (50.97%)	148,664 (50.22%)	273,555 (49.58%)	309,380 (47.38%)	340,224 (45.38%)
65+	23,899 (30.29%)	26,568 (30.47%)	43,442 (29.58%)	76,258 (25.76%)	132,303 (23.98%)	162,843 (24.94%)	195,166 (26.03%)
Sex							
Female	43,494 (55.13%)	47,811 (54.84%)	86,059 (58.59%)	188,801 (63.78%)	365,204 (66.19%)	430,029 (65.86%)	485,857 (64.80%)
Male	35,395 (44.87%)	39,371 (45.16%)	60,821 (41.41%)	107,210 (36.22%)	186,558 (33.81%)	222,920 (34.14%)	263,865 (35.20%)
Race							
White	59,187 (75.03%)	64,030 (73.44%)	106,318 (72.38%)	213,546 (72.14%)	393,623 (71.34%)	466,748 (71.48%)	532,936 (71.08%)
Black or African American	9,999 (12.67%)	11,591 (13.30%)	20,468 (13.94%)	42,155 (14.24%)	80,836 (14.65%)	86,210 (13.20%)	94,424 (12.59%)
Asian	1,878 (2.38%)	2,303 (2.64%)	4,255 (2.90%)	7,387 (2.50%)	13,400 (2.43%)	16,431 (2.52%)	19,372 (2.58%)
Unknown	4,402 (5.58%)	5,099 (5.85%)	8,266 (5.63%)	16,674 (5.63%)	33,731 (6.11%)	47,919 (7.34%)	62,640 (8.36%)
Native Hawaiian or Other Pacific Islander	299 (0.38%)	368 (0.42%)	629 (0.43%)	1,147 (0.39%)	1,885 (0.34%)	2,311 (0.35%)	2,579 (0.34%)
American Indian or Alaska Native	663 (0.84%)	691 (0.79%)	1,298 (0.88%)	2,329 (0.79%)	3,832 (0.69%)	4,468 (0.68%)	4,642 (0.62%)
Other Race	2,461 (3.12%)	3,100 (3.56%)	5,646 (3.84%)	12,773 (4.32%)	24,455 (4.43%)	28,862 (4.42%)	33,129 (4.42%)
Ethnicity							
Hispanic or Latino	7,766 (9.84%)	9,449 (10.84%)	17,500 (11.91%)	36,910 (12.47%)	65,862 (11.94%)	79,542 (12.18%)	90,086 (12.02%)
Not Hispanic or Latino	66,484 (84.28%)	72,553 (83.22%)	121,473 (82.70%)	243,492 (82.26%)	455,970 (82.64%)	535,323 (81.99%)	608,678 (81.19%)
Unknown	4,639 (5.88%)	5,180 (5.94%)	7,907 (5.38%)	15,609 (5.27%)	29,930 (5.42%)	38,084 (5.83%)	50,958 (6.80%)
Characteristics							
Type II Diabetes	58,614 (74.30%)	62,856 (72.10%)	95,030 (64.70%)	152,874 (51.64%)	239,700 (43.44%)	239,638 (36.70%)	230,295 (30.72%)

	2019	2020	2021	2022	2023	2024	2025
Overweight or Obesity	49,774 (63.09%)	52,452 (60.16%)	92,265 (62.82%)	185,573 (62.69%)	372,068 (67.43%)	450,641 (69.02%)	506,170 (67.51%)
Medication							
Semaglutide	17,750 (22.50%)	31,181 (35.77%)	71,561 (48.72%)	168,454 (56.91%)	377,133 (68.35%)	395,872 (60.63%)	332,274 (44.32%)
Tirzepatide	n/a	n/a	n/a	26,129 (8.83%)	73,838 (13.38%)	202,078 (30.95%)	379,404 (50.61%)
Liraglutide	24,319 (30.83%)	18,490 (21.21%)	22,395 (15.25%)	26,081 (8.81%)	23,625 (4.28%)	10,062 (1.54%)	6,664 (0.89%)
Dulaglutide	29,117 (36.91%)	31,739 (36.41%)	48,025 (32.70%)	70,297 (23.75%)	72,629 (13.16%)	41,699 (6.39%)	29,631 (3.95%)
Other	7,703 (9.76%)	5,772 (6.62%)	4,899 (3.34%)	5,050 (1.71%)	4,537 (0.82%)	3,238 (0.50%)	1,749 (0.23%)
Labeled Use							
ADM	47,054 (59.65%)	60,578 (69.48%)	107,856 (73.43%)	209,475 (70.77%)	316,576 (57.38%)	289,984 (44.41%)	276,696 (36.91%)
AOM	2,352 (2.98%)	3,427 (3.93%)	9,190 (6.26%)	22,378 (7.56%)	93,340 (16.92%)	180,774 (27.69%)	262,467 (35.01%)
Unknown	29,483 (37.37%)	23,177 (26.58%)	29,834 (20.31%)	64,158 (21.67%)	141,846 (25.71%)	182,191 (27.90%)	210,559 (28.08%)
Comorbidity							
Asthma	9,697 (12.29%)	10,876 (12.48%)	19,451 (13.24%)	39,504 (13.35%)	77,476 (14.04%)	93,922 (14.38%)	106,864 (14.25%)
CKD	14,282 (18.10%)	16,750 (19.21%)	27,035 (18.41%)	42,622 (14.40%)	66,649 (12.08%)	72,950 (11.17%)	79,668 (10.63%)
COPD	5,272 (6.68%)	5,986 (6.87%)	8,994 (6.12%)	14,969 (5.06%)	26,693 (4.84%)	31,446 (4.82%)	35,224 (4.70%)
Hyperlipidemia	47,580 (60.31%)	50,932 (58.42%)	81,847 (55.72%)	149,999 (50.67%)	271,893 (49.28%)	320,618 (49.10%)	358,020 (47.75%)
Hypertension	50,567 (64.10%)	53,832 (61.75%)	86,577 (58.94%)	157,842 (53.32%)	284,921 (51.64%)	327,808 (50.20%)	356,507 (47.55%)
Major Depression	9,216 (11.68%)	10,430 (11.96%)	19,492 (13.27%)	37,338 (12.61%)	63,607 (11.53%)	72,962 (11.17%)	80,496 (10.74%)

60-day dispensing over time

We describe the proportion of patients with any GLP-1 RA prescriptions (first-time and repeat) in a given month who filled any GLP-1 RA in the 60 days following their prescription.



60-day initiation over time

We describe the proportion of patients first-prescribed a GLP-1 RA who filled any GLP-1 RA in the subsequent 60 days over time.



Patient characteristics are given in Table 3:

Table 3: Patient Characteristics by Dispense Status. Dispense status refers to presence of any GLP-1 RA dispense within 60 days of first GLP-1 RA prescription. Table contains the subset of patients with observable 60-day dispense outcomes.

	Dispensed in 60 Days	Not Dispensed in 60 Days	Overall
N	1,489,307 (100.00%)	1,088,427 (100.00%)	2,577,734 (100.00%)
Age Group			
18-44	342,922 (23.03%)	326,806 (30.03%)	669,728 (25.98%)
45-64	734,803 (49.34%)	506,229 (46.51%)	1,241,032 (48.14%)
65+	411,582 (27.64%)	255,392 (23.46%)	666,974 (25.87%)
Sex			
Female	921,806 (61.89%)	733,947 (67.43%)	1,655,753 (64.23%)
Male	567,501 (38.11%)	354,480 (32.57%)	921,981 (35.77%)
Race			

	Dispensed in 60 Days	Not Dispensed in 60 Days	Overall
White	1,050,424 (70.53%)	798,414 (73.35%)	1,848,838 (71.72%)
Black or African American	206,561 (13.87%)	141,939 (13.04%)	348,500 (13.52%)
Asian	41,472 (2.78%)	24,491 (2.25%)	65,963 (2.56%)
Unknown	107,597 (7.22%)	69,528 (6.39%)	177,125 (6.87%)
Native Hawaiian or Other Pacific Islander	5,864 (0.39%)	3,494 (0.32%)	9,358 (0.36%)
American Indian or Alaska Native	10,611 (0.71%)	7,298 (0.67%)	17,909 (0.69%)
Other Race	66,778 (4.48%)	43,263 (3.97%)	110,041 (4.27%)
Ethnicity			
Hispanic or Latino	182,459 (12.25%)	125,822 (11.56%)	308,281 (11.96%)
Not Hispanic or Latino	1,215,063 (81.59%)	903,517 (83.01%)	2,118,580 (82.19%)
Unknown	91,785 (6.16%)	59,088 (5.43%)	150,873 (5.85%)
Characteristics			
Type II Diabetes	757,228 (50.84%)	327,794 (30.12%)	1,085,022 (42.09%)
Overweight or Obesity	959,595 (64.43%)	805,106 (73.97%)	1,764,701 (68.46%)
Medication			
Semaglutide	777,170 (52.18%)	613,154 (56.33%)	1,390,324 (53.94%)
Tirzepatide	389,626 (26.16%)	323,865 (29.76%)	713,491 (27.68%)
Liraglutide	74,189 (4.98%)	53,811 (4.94%)	128,000 (4.97%)
Dulaglutide	228,102 (15.32%)	86,118 (7.91%)	314,220 (12.19%)
Other	20,220 (1.36%)	11,479 (1.05%)	31,699 (1.23%)
Labeled Use			
ADM	906,740 (60.88%)	390,701 (35.90%)	1,297,441 (50.33%)
AOM	274,181 (18.41%)	326,052 (29.96%)	600,233 (23.29%)
Unknown	308,386 (20.71%)	371,674 (34.15%)	680,060 (26.38%)
Year			
2019	47,216 (3.17%)	30,209 (2.78%)	77,425 (3.00%)
2020	52,490 (3.52%)	33,125 (3.04%)	85,615 (3.32%)
2021	91,217 (6.12%)	53,258 (4.89%)	144,475 (5.60%)
2022	187,836 (12.61%)	101,296 (9.31%)	289,132 (11.22%)

	Dispensed in 60 Days	Not Dispensed in 60 Days	Overall
2023	333,736 (22.41%)	206,903 (19.01%)	540,639 (20.97%)
2024	356,211 (23.92%)	274,258 (25.20%)	630,469 (24.46%)
2025	359,735 (24.15%)	332,740 (30.57%)	692,475 (26.86%)
2026	60,866 (4.09%)	56,638 (5.20%)	117,504 (4.56%)
Comorbidity			
Asthma	201,090 (13.50%)	166,471 (15.29%)	367,561 (14.26%)
CKD	208,349 (13.99%)	119,863 (11.01%)	328,212 (12.73%)
COPD	80,769 (5.42%)	50,996 (4.69%)	131,765 (5.11%)
Hyperlipidemia	766,171 (51.44%)	549,325 (50.47%)	1,315,496 (51.03%)
Hypertension	786,332 (52.80%)	554,464 (50.94%)	1,340,796 (52.01%)
Major Depression	159,504 (10.71%)	145,615 (13.38%)	305,119 (11.84%)

By Age

As a proxy for Medicare insurance, we segment initiation rate by populations 65+ versus 18-64.



Patient characteristics for patients aged 65+ are given in Table 4:

Table 4: Patient Characteristics by Dispense Status, Age 65+. Dispense status refers to presence of any GLP-1 RA dispense within 60 days of first GLP-1 RA prescription. Table contains the subset of patients with observable 60-day dispense outcomes.

	Dispensed in 60 Days	Not Dispensed in 60 Days	Overall
N	411,582 (100.00%)	255,392 (100.00%)	666,974 (100.00%)
Age Group			
65+	411,582 (100.00%)	255,392 (100.00%)	666,974 (100.00%)
Sex			
Female	227,596 (55.30%)	147,920 (57.92%)	375,516 (56.30%)
Male	183,986 (44.70%)	107,472 (42.08%)	291,458 (43.70%)
Race			
White	318,176 (77.31%)	206,975 (81.04%)	525,151 (78.74%)
Black or African American	40,809 (9.92%)	23,135 (9.06%)	63,944 (9.59%)
Asian	9,382 (2.28%)	4,048 (1.59%)	13,430 (2.01%)
Unknown	26,556 (6.45%)	13,770 (5.39%)	40,326 (6.05%)
Native Hawaiian or Other Pacific Islander	909 (0.22%)	421 (0.16%)	1,330 (0.20%)
American Indian or Alaska Native	2,158 (0.52%)	1,165 (0.46%)	3,323 (0.50%)
Other Race	13,592 (3.30%)	5,878 (2.30%)	19,470 (2.92%)
Ethnicity			
Hispanic or Latino	31,132 (7.56%)	14,836 (5.81%)	45,968 (6.89%)
Not Hispanic or Latino	352,813 (85.72%)	225,282 (88.21%)	578,095 (86.67%)
Unknown	27,637 (6.71%)	15,274 (5.98%)	42,911 (6.43%)
Characteristics			
Type II Diabetes	266,541 (64.76%)	122,504 (47.97%)	389,045 (58.33%)
Overweight or Obesity	251,203 (61.03%)	172,668 (67.61%)	423,871 (63.55%)
Medication			
Semaglutide	219,504 (53.33%)	143,394 (56.15%)	362,898 (54.41%)
Tirzepatide	87,172 (21.18%)	61,523 (24.09%)	148,695 (22.29%)
Liraglutide	16,480 (4.00%)	11,633 (4.55%)	28,113 (4.22%)
Dulaglutide	79,471 (19.31%)	33,901 (13.27%)	113,372 (17.00%)
Other	8,955 (2.18%)	4,941 (1.93%)	13,896 (2.08%)
Labeled Use			
ADM	296,498 (72.04%)	122,777 (48.07%)	419,275 (62.86%)

	Dispensed in 60 Days	Not Dispensed in 60 Days	Overall
AOM	28,832 (7.01%)	52,047 (20.38%)	80,879 (12.13%)
Unknown	86,252 (20.96%)	80,568 (31.55%)	166,820 (25.01%)
Year			
2019	13,696 (3.33%)	9,633 (3.77%)	23,329 (3.50%)
2020	15,507 (3.77%)	10,413 (4.08%)	25,920 (3.89%)
2021	26,413 (6.42%)	16,085 (6.30%)	42,498 (6.37%)
2022	48,171 (11.70%)	25,485 (9.98%)	73,656 (11.04%)
2023	89,226 (21.68%)	39,813 (15.59%)	129,039 (19.35%)
2024	96,536 (23.45%)	60,281 (23.60%)	156,817 (23.51%)
2025	103,658 (25.19%)	77,866 (30.49%)	181,524 (27.22%)
2026	18,375 (4.46%)	15,816 (6.19%)	34,191 (5.13%)
Comorbidity			
Asthma	49,762 (12.09%)	33,778 (13.23%)	83,540 (12.53%)
CKD	121,193 (29.45%)	69,395 (27.17%)	190,588 (28.58%)
COPD	42,349 (10.29%)	26,977 (10.56%)	69,326 (10.39%)
Hyperlipidemia	270,736 (65.78%)	181,815 (71.19%)	452,551 (67.85%)
Hypertension	282,279 (68.58%)	185,702 (72.71%)	467,981 (70.16%)
Major Depression	43,285 (10.52%)	31,941 (12.51%)	75,226 (11.28%)

Patient characteristics for patients aged 18-65 are given in Table 5:

Table 5: Patient Characteristics by Dispense Status, Age 18-64. Dispense status refers to presence of any GLP-1 RA dispense within 60 days of first GLP-1 RA prescription. Table contains the subset of patients with observable 60-day dispense outcomes.

	Dispensed in 60 Days	Not Dispensed in 60 Days	Overall
N	1,077,725 (100.00%)	833,035 (100.00%)	1,910,760 (100.00%)
Age Group			
18-44	342,922 (31.82%)	326,806 (39.23%)	669,728 (35.05%)
45-64	734,803 (68.18%)	506,229 (60.77%)	1,241,032 (64.95%)
Sex			
Female	694,210 (64.41%)	586,027 (70.35%)	1,280,237 (67.00%)
Male	383,515 (35.59%)	247,008 (29.65%)	630,523 (33.00%)

	Dispensed in 60 Days	Not Dispensed in 60 Days	Overall
Race			
White	732,248 (67.94%)	591,439 (71.00%)	1,323,687 (69.28%)
Black or African American	165,752 (15.38%)	118,804 (14.26%)	284,556 (14.89%)
Asian	32,090 (2.98%)	20,443 (2.45%)	52,533 (2.75%)
Unknown	81,041 (7.52%)	55,758 (6.69%)	136,799 (7.16%)
Native Hawaiian or Other Pacific Islander	4,955 (0.46%)	3,073 (0.37%)	8,028 (0.42%)
American Indian or Alaska Native	8,453 (0.78%)	6,133 (0.74%)	14,586 (0.76%)
Other Race	53,186 (4.94%)	37,385 (4.49%)	90,571 (4.74%)
Ethnicity			
Hispanic or Latino	151,327 (14.04%)	110,986 (13.32%)	262,313 (13.73%)
Not Hispanic or Latino	862,250 (80.01%)	678,235 (81.42%)	1,540,485 (80.62%)
Unknown	64,148 (5.95%)	43,814 (5.26%)	107,962 (5.65%)
Characteristics			
Type II Diabetes	490,687 (45.53%)	205,290 (24.64%)	695,977 (36.42%)
Overweight or Obesity	708,392 (65.73%)	632,438 (75.92%)	1,340,830 (70.17%)
Medication			
Semaglutide	557,666 (51.74%)	469,760 (56.39%)	1,027,426 (53.77%)
Tirzepatide	302,454 (28.06%)	262,342 (31.49%)	564,796 (29.56%)
Liraglutide	57,709 (5.35%)	42,178 (5.06%)	99,887 (5.23%)
Dulaglutide	148,631 (13.79%)	52,217 (6.27%)	200,848 (10.51%)
Other	11,265 (1.05%)	6,538 (0.78%)	17,803 (0.93%)
Labeled Use			
ADM	610,242 (56.62%)	267,924 (32.16%)	878,166 (45.96%)
AOM	245,349 (22.77%)	274,005 (32.89%)	519,354 (27.18%)
Unknown	222,134 (20.61%)	291,106 (34.95%)	513,240 (26.86%)
Year			
2019	33,520 (3.11%)	20,576 (2.47%)	54,096 (2.83%)
2020	36,983 (3.43%)	22,712 (2.73%)	59,695 (3.12%)
2021	64,804 (6.01%)	37,173 (4.46%)	101,977 (5.34%)
2022	139,665 (12.96%)	75,811 (9.10%)	215,476 (11.28%)
2023	244,510 (22.69%)	167,090 (20.06%)	411,600 (21.54%)

	Dispensed in 60 Days	Not Dispensed in 60 Days	Overall
2024	259,675 (24.09%)	213,977 (25.69%)	473,652 (24.79%)
2025	256,077 (23.76%)	254,874 (30.60%)	510,951 (26.74%)
2026	42,491 (3.94%)	40,822 (4.90%)	83,313 (4.36%)
Comorbidity			
Asthma	151,328 (14.04%)	132,693 (15.93%)	284,021 (14.86%)
CKD	87,156 (8.09%)	50,468 (6.06%)	137,624 (7.20%)
COPD	38,420 (3.56%)	24,019 (2.88%)	62,439 (3.27%)
Hyperlipidemia	495,435 (45.97%)	367,510 (44.12%)	862,945 (45.16%)
Hypertension	504,053 (46.77%)	368,762 (44.27%)	872,815 (45.68%)
Major Depression	116,219 (10.78%)	113,674 (13.65%)	229,893 (12.03%)

Discussion and Conclusion

This analysis summarized GLP-1 RA prescribing trends and patient characteristics from January 2019 to March 2026. During this period 2,855,602 patients were prescribed a total of 14,738,765 total prescriptions. ADMs accounted for 71.2% of prescriptions, and AOMs accounted for 28.8%, among prescriptions where use was known. A larger proportion of ADMs, compared to AOMs, were dispensed within 60 days: 69.9% of first-time ADM prescriptions and 45.7% of first-time AOM prescriptions had a fill within 60 days.

Several limitations of our analysis should be noted. All data are preliminary and may change as additional data are obtained. These findings are consistent with data accessed April 13, 2026. Data presented in this analysis represent raw counts and/or rates, and post-stratification methods have not been conducted. In addition, cohorts with small counts may be suppressed during the de-identification process leading to the appearance of zero patients for a given time period. Given relatively large numbers of patients prescribed and dispensed GLP-1 RA, we do not expect substantial suppression in the most recent periods. The unknowns in this report either indicate the value was not included in the individual's electronic health record or that it was excluded from the data to protect an individual's identity as a part of Truveta's commitment to privacy (Truveta, 2024). Finally, this report is a description of prescribing trends and patient characteristics only. Results should not be interpreted as causal.

References

Truveta. (2024). Truveta's Approach to Patient Privacy. https://resources.truveta.com/patient-privacy

Centers for disease control and prevention. "National diabetes statistics report". 2020. https://www.cdc.gov/diabetes/data/statistics-report/index.html.

Davies, Melanie J., et al. "Efficacy of liraglutide for weight loss among patients with type 2 diabetes: the SCALE diabetes randomized clinical trial." JAMA 314.7 (2015): 687-699.

Davies, Melanie, et al. "Semaglutide 2· 4 mg once a week in adults with overweight or obesity, and type 2 diabetes (STEP 2): a randomised, double-blind, double-dummy, placebo-controlled, phase 3 trial." The Lancet 397.10278 (2021): 971-984.

Hales, Craig M., et al. "Prevalence of obesity and severe obesity among adults: United States, 2017–2018. NCHS Data Brief, no 360." National Center for Health Statistics 360 (2020): 1-7.

Han, Sabrina H., et al. "Public interest in the off-label use of glucagon-like peptide 1 agonists (Ozempic) for cosmetic weight loss: a google trends analysis." Aesthetic Surgery Journal 44.1 (2024): 60-67.

Garvey, W. Timothy, et al. "Tirzepatide once weekly for the treatment of obesity in people with type 2 diabetes (SURMOUNT-2): a double-blind, randomised, multicentre, placebo-controlled, phase 3 trial." The Lancet (2023).

Jastreboff, Ania M., et al. "Tirzepatide once weekly for the treatment of obesity." New England Journal of Medicine 387.3 (2022): 205-216.

Lincoff, A. Michael, et al. "Semaglutide and cardiovascular outcomes in obesity without diabetes." New England Journal of Medicine 389.24 (2023): 2221-2232.

Ussher, John R., and Daniel J. Drucker. "Glucagon-like peptide 1 receptor agonists: cardiovascular benefits and mechanisms of action." Nature Reviews Cardiology 20.7 (2023): 463-474.

Wilding, John PH, et al. "Once-weekly semaglutide in adults with overweight or obesity." New England Journal of Medicine 384.11 (2021): 989-1002.

Whitley, Heather P., Jennifer M. Trujillo, and Joshua J. Neumiller. "Potential Strategies for Addressing GLP-1 and Dual GLP-1/GIP Receptor Agonist Shortages." Clinical Diabetes (2023): cd230023.

Yeh, Tzu-Lin, et al. “Effect of glucagon-like peptide-1 receptor agonists on glycemic control, and weight reduction in adults: A multivariate meta-analysis.” PLOS One 18.1 (2023): e0278685.

Acknowledgements

The authors thank Drs. Nick Stucky, Tricia Rodriquez, and Ty Gluckman for their contributions and feedback on describing GLP-1 RA prescribing trends.